NOAELTAXEL
DEAD

Serial Number

79290127

Owner

CnPharm Co., Ltd.

Filing Date

Jun 16, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NOAELTAXEL Trademark

Serial Number: 79290127

NOAELTAXEL is a trademark filed by CnPharm Co., Ltd. on June 16, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CnPharm Co., Ltd. (16 trademarks)

B-455, 52, Ewhayeodae-gil, Seodaemun-gu

Entity Type: 03

Trademark Details

Filing Date

June 16, 2020

Registration Date

Not Registered

Goods & Services

Medicines for the treatment of gastrointestinal diseases; injectable mineral solutions for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; suppositories; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for dental purposes; haemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for anus; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood thinners; pharmaceutical preparations for respiratory organs; respiratory stimulants; Pharmaceutical preparations; pharmaceutical agents affecting sensory organs; thyroid and para-thyroid hormone preparations; tonics [medicines]; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for urogenital organs; vitamin preparations; pharmaceutical products for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; nervines; ophthalmic preparations; allergy medications; chemico-pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical products for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of rhinitis; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated mouth treatment preparations; transdermal patches for medical treatment; pharmaceutical preparations for the treatment of gout; drug delivery agents; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 30, 2022 FINT
FINAL DISPOSITION NOTICE SENT TO IB
May 4, 2022 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 4, 2022 FICR
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Mar 27, 2022 DENA
DEATH OF INTERNATIONAL REGISTRATION
Mar 26, 2022 DETH
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 15, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 29, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 29, 2021 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 3, 2021 NREP
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 4, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 4, 2021 ABN2
REFUSAL PROCESSED BY IB
Nov 8, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 19, 2020 RFCS
REFUSAL PROCESSED BY MPU
Oct 19, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 24, 2020 RFCR
NON-FINAL ACTION WRITTEN
Sep 23, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 28, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 23, 2020 REPR